✨ Free AI Report
Oncodesign Precision Medicine: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Oncodesign Precision Medicine
Company Research

Oncodesign Precision Medicine: Business Overview, Financials & Competitive Analysis

Oncodesign Precision Medicine scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage precision oncology company with promising lead programs in clinical trials, facing capital constraints in a challenging biotech funding environment. The company achieved a 19% reduction in operating expenses and 21% improvement in operating income in 2024, demonstrating cost discipline. However, the termination of collaboration with Servier impacted 2025.

What is Oncodesign Precision Medicine's industry? Oncodesign Precision Medicine (oncodesign.com) operates in Biopharmaceutical/Precision Oncology. AskCyborg classifies Oncodesign Precision Medicine under Biopharmaceutical/Precision Oncology in its company registry.

Oncodesign Precision Medicine is a biopharmaceutical company specializing in precision medicine with a pipeline including OPM-101 (a RIPK2 inhibitor for inflammatory bowel disease and immuno-oncology), OPM-102 for can...

5/ 10Mixed

Cyborg Score thesis

Early-stage precision oncology company with promising lead programs in clinical trials, facing capital constraints in a...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Precision Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Oncodesign Precision Medicine Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Oncodesign Precision Medicine

AskCyborg analysts argue the bull and bear cases for Oncodesign Precision Medicine across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Oncodesign Precision Medicine OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Oncodesign Precision Medicine Overview

Pro stress-test →

Oncodesign Precision Medicine is a biopharmaceutical company specializing in precision medicine with a pipeline including OPM-101 (a RIPK2 inhibitor for inflammatory bowel disease and immuno-oncology), OPM-102 for cancer treatment, and OPM-201 (a LRRK2 inhibitor for Parkinson's disease). The company aims to provide effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Strategic Profile

Pro stress-test →

The company leverages innovative technologies including OncoSNIPER for therapeutic target selection using AI, Nanocyclix® for designing macrocyclic kinase inhibitors, and Promethe for developing radiolabeled molecules for radiotherapy. OPM-101 has advanced to Phase 1b/2a clinical trials (REVERT study) in advanced melanoma patients resistant to anti-PD-1 therapy.

Competitive Landscape

Pro stress-test →

OPM competes in the immuno-oncology space where anti-PD-1 checkpoint inhibitors dominate but face significant resistance and toxicity issues. OPM-101's RIPK2 inhibitor approach targets these limitations by potentially increasing response rates and reducing immune-related side effects of existing therapies. The company faces competition from larger pharma and specialized immuno-oncology biotech firms.

Industry Context

Oncodesign Precision Medicine operates in Biopharmaceutical/Precision Oncology.

Key facts

Founded: 1995 · Headquarters: Dijon, France · Revenue: $225K (trailing 12M) · Market cap: $15.7M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Oncodesign Precision Medicine.

  • OPM-101 demonstrated positive Phase 1 results in October 2024, supporting advancement to patient studies
  • OPM reacquired OPM-201 (Parkinson's LRRK2 inhibitor) rights from Servier after completed Phase I safety trials, retaining full control of neurology asset
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2025Secured €5 million equity financing line to strengthen cash position
  • April 2025Announced 2024 financial results with 19% reduction in operating expenses
  • +2 moreTrack every material event for Oncodesign Precision Medicine as it happens. Explore monitoring →
Get alerted when Oncodesign Precision Medicine has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Anti-PD-1 Checkpoint InhibitorsStandard-of-care immunotherapy for resistant cancers with toxicity and resistance challenges→LRRK2 Kinase Inhibitors (Neurology)Competing approaches for Parkinson's disease targeting LRRK2 pathway→Precision Oncology PlatformsAI-driven diagnostic and therapeutic selection for cancer treatment→

Compare Oncodesign Precision Medicine with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Oncodesign Precision Medicine operates in Biopharmaceutical/Precision Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Precision Oncology research →
NEW · MCP server

Ask your AI assistant about Oncodesign Precision Medicine

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Oncodesign Precision Medicine and its top competitor on Cyborg Score”
“What did Oncodesign Precision Medicine do this quarter?”
“Is Oncodesign Precision Medicine a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Oncodesign Precision Medicine do?+
Oncodesign Precision Medicine is a biopharmaceutical company specializing in precision medicine with a pipeline including OPM-101 (a RIPK2 inhibitor for inflammatory bowel disease and immuno-oncology), OPM-102 for can...
What is Oncodesign Precision Medicine's Cyborg Score?+
Oncodesign Precision Medicine has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Oncodesign Precision Medicine's main competitors?+
Named competitors include Anti-PD-1 Checkpoint Inhibitors, LRRK2 Kinase Inhibitors (Neurology), Precision Oncology Platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Oncodesign Precision Medicine research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Oncodesign Precision Medicine research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Oncodesign Precision Medicine over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score